ClinicalTrials.gg
CompletedNCT05929066TRIUMPH-1Updated Aug 21, 2026

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight

A Phase 3 interventional study of Retatrutide and Placebo in Obesity, Overweight and Osteoarthritis, Knee, sponsored by Eli Lilly and Company. Completed at 134 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-21.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,335
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing retatrutide in Obesity — 1 open to participants now, 6 under way, 5 of them phase 3. retatrutide · Obesity.

Enrollment
Largest of 16
2,335 · median 392
Started
2023
with 5 others
Phase 3
9 of 16
none open now
Registered
5th of 16
by date
Lead sponsor
15 of 16
Eli Lilly and Company

Among the 16 studies testing retatrutide in Obesity, this one has the largest enrollment, is one of 6 that started in 2023, is one of 9 in phase 3, and was the 5th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

1 of the 16 studies testing retatrutide in Obesity is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About retatrutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing retatrutide in Obesity, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master protocol) including subsets of participants who have knee osteoarthritis (OA) (J1I-MC-GOA1) or who have obstructive sleep apnea (OSA) (J1I-MC-GSA1). This study will last about 89 weeks and will include up to 24 visits. Addendum (2) is optional and available to approximately 500 participants to continue treatment with retatrutide for up to an additional 24 weeks.

03

Conditions studied

  • Obesity
  • Overweight
  • Osteoarthritis, Knee
  • Obstructive Sleep Apnea
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have (BMI) ≥30.0 kilograms per square meter (kg/m²), or ≥27.0 kg/m² with at least one of the following:

    • hypertension
    • dyslipidemia
    • obstructive sleep apnea, or
    • cardiovascular disease
  • History of at least one unsuccessful dietary effort to reduce body weight

GOA1 Inclusion Criteria:

  • Have index knee pain for >12 weeks prior to screening, and presence of index knee pain for >15 days over the previous month
  • Have knee X-ray with moderate radiographic changes (Kellgren-Lawrence Grade 2 or 3) per central reading at screening
  • Currently meets American College of Rheumatology (ACR) Criteria (clinical and radiological) for OA.

GSA1 Inclusion Criteria:

  • Previously diagnosed with OSA
  • Have AHI ≥15 on polysomnography at screening (definition of moderate-to-severe OSA)
  • For participants not on positive airway pressure (PAP) therapy: unable or unwilling to use PAP therapy and have not used PAP for at least 4 weeks prior to screening.
  • If on PAP therapy, have been on PAP therapy for at least 3 consecutive months prior to screening, and willing to temporarily stop using PAP therapy for approximately 7 days prior to each of the sleep study (PSG) visits.

GZBJ Addenda (2) inclusion criteria:

  • Have completed the final treatment visit of GZBJ Week 80.

Exclusion criteria

Exclusion Criteria:

  • Have a self-reported or documented change in body weight >5 kg (11 pounds) within 90 days.
  • Have taken weight loss drugs, including over-the-counter medications, within 90 days prior to screening.
  • Have a prior or planned surgical treatment for obesity.
  • Have diabetes mellitus.
  • Have family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
  • Have had pancreatitis.

GOA1 exclusion criteria

  • Have had joint injections within 90 days of screening.
  • Have had other joint injections and procedures within 6 months of screening.
  • Have joint disease other than osteoarthritis.

GSA1 exclusion criteria

  • Use stimulants (for example, modafinil, armodafinil, solriamfetol, pitolisant, amphetamine) less than 3 months prior to screening.
  • Use hypnotics, mirtazapine, opioids, trazodone, and zonisamide less than 3 months prior to screening.
  • Use a dental appliance or other device to treat OSA other than PAP therapy.

GZBJ Addenda (2) exclusion criteria

  • Have had study intervention discontinuation.
  • Have had permanent dose reduction.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
2,335 participants (actual)

Study arms

  • Experimental
    Retatrutide Dose 1

    Participants will receive retatrutide subcutaneously (SC).

    Drug: Retatrutide

  • Experimental
    Retatrutide Dose 2

    Participants will receive retatrutide SC.

    Drug: Retatrutide

  • Experimental
    Retatrutide Dose 3

    Participants will receive retatrutide SC.

    Drug: Retatrutide

  • Placebo comparator
    Placebo

    Participants will receive placebo.

    Drug: Placebo

  • Experimental
    Retatrutide Extension Period

    Participants will receive retatrutide after the placebo-controlled 80 week treatment period for an additional 24 weeks.

    Drug: Retatrutide

Interventions

  • Administered SC

    Also known as: LY3437943

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Body Weight

    Time frame: Baseline, Week 80

  2. Change from Baseline in Apnea-Hypopnea Index (AHI) Events Per Hour for GSA1 Subset

    Time frame: Baseline, Week 80

  3. Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score for GOA1 Subset

    Time frame: Baseline, Week 80

  4. Percent Change from Baseline in Body Weight in Participants in Extension Subset

    Time frame: Baseline, Week 104

Secondary outcomes

  1. Percent Change from Baseline in Body Weight in Participants with Baseline BMI ≥ 35 kg/m2

    Time frame: Baseline, Week 80

  2. Percentage of Participants who Achieve Body Weight Reduction of ≥ 5%

    Time frame: Baseline through Week 80

  3. Percentage of Participants who Achieve Body Weight Reduction of ≥ 10%

    Time frame: Baseline through Week 80

  4. Percentage of Participants who Achieve Body Weight Reduction of ≥ 15%

    Time frame: Baseline through Week 80

  5. Percentage of Participants who Achieve Body Weight Reduction of ≥ 20%

    Time frame: Baseline through Week 80

  6. Percentage of Participants who Achieve Body Weight Reduction of ≥ 25%

    Time frame: Baseline through Week 80

  7. Percentage of Participants who Achieve Body Weight Reduction of ≥ 30%

    Time frame: Baseline through Week 80

  8. Percentage of Participants who Achieve Body Weight Reduction of ≥ 35%

    Time frame: Baseline through Week 80

  9. Change from Baseline in Waist Circumference

    Time frame: Baseline, Week 80

  10. Change from Baseline in Systolic Blood Pressure (SBP)

    Time frame: Baseline, Week 80

  11. Percent Change from Baseline in Triglycerides

    Time frame: Baseline, Week 80

  12. Percent Change from Baseline in Non-High-Density Lipoprotein (HDL)-Cholesterol

    Time frame: Baseline, Week 80

  13. Percent Change form Baseline in Fasting Insulin

    Time frame: Baseline, Week 80

  14. Percent Change from Baseline in High-Sensitivity C-Reactive Protein (hsCRP)

    Time frame: Baseline, Week 80

  15. Change from Baseline in Short Form 36 Version 2 (SF-36v2) Acute Form Physical Functioning Domain Score

    Time frame: Baseline, Week 80

  16. Change from Baseline in Impact of Weight on Quality of Life-Lite Clinical Trial (IWQOL-Lite-CT) Physical Function Composite Score

    Time frame: Baseline, Week 80

  17. Change from Baseline in IWQOL-Lite-CT Psychosocial Composite Score

    Time frame: Baseline, Week 80

  18. Change from Baseline in Body Mass Index (BMI)

    Time frame: Baseline, Week 80

  19. Percentage of Participants who Achieve Waist-to-Height Ratio (WHtR) <0.5

    Time frame: Baseline through Week 80

  20. Change from Baseline in HbA1c

    Time frame: Baseline, Week 80

  21. Change from Baseline in Estimated Glomerular Filtration Rate (eGFR)

    Time frame: Baseline, Week 80

  22. Percentage of Participants with a Change in Medication Use

    Time frame: Baseline through Week 80

  23. Percentage of Participants who Develop Type 2 Diabetes

    Time frame: Baseline through Week 80

  24. Time to Onset of Type 2 Diabetes

    Time frame: Baseline through Week 80

  25. Percent Change from Baseline in AHI for GSA1 Subset

    Time frame: Baseline, Week 80

  26. Percentage of Participants with ≥50% AHI Reduction from Baseline for GSA1 Subset

    Time frame: Baseline to Week 80

  27. Percentage of Participants with AHI <5 or with AHI 5-14 with Epworth Sleepiness Scale (ESS) ≤10 for GSA1 Subset

    Time frame: Week 80

  28. Percent Change from Baseline in Sleep Apnea-Specific Hypoxic Burden for GSA1 Subset

    Time frame: Baseline, Week 80

  29. Change from Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form Sleep-related Impairment 8a T-score for GSA1 Subset

    Time frame: Baseline, Week 80

  30. Change from Baseline in AHI Events Per Hour for GSA1 Subset in Participants with Baseline Body Mass Index (BMI) ≥ 35 kg/m2

    Time frame: Baseline, Week 80

  31. Percentage of Participants who Achieve AHI < 5 for GSA1 Subset

    Time frame: Baseline, Week 80

  32. Change from Baseline in ESS Score for GSA1 Subset

    Time frame: Baseline, Week 80

  33. Change from Baseline in Functional Outcomes of Sleep Questionnaire (FOSQ) Total Score

    Time frame: Baseline to Week 80

  34. Change from Baseline in PROMIS Sleep Disturbance Short Form 8b T-Score for GSA1 Subset

    Time frame: Baseline, Week 80

  35. Change from Baseline in Neck Circumference for GSA1 Subset

    Time frame: Baseline, Week 80

  36. Change from Baseline in the WOMAC Physical Function Subscale Score for GOA1 Subset

    Time frame: Baseline, Week 80

  37. Percentage of Participants who Achieve ≥ 50% Reduction in the WOMAC Pain Subscale for GOA1 Subset

    Time frame: Baseline through Week 80

  38. Percentage of Participants who Achieve ≥ 50% Reduction in the WOMAC Physical Function Subscale for GOA1 Subset

    Time frame: Baseline through Week 80

  39. Change from Baseline in the WOMAC Pain Subscale Score for GOA1 Subset with Baseline BMI ≥ 35 kg/m2

    Time frame: Baseline, Week 80

  40. Change from Baseline in the WOMAC Stiffness Subscale Score for GOA1 Subset

    Time frame: Baseline, Week 80

  41. Change from Baseline in the WOMAC Total Score for GOA1 Subset

    Time frame: Baseline, Week 80

  42. Change from Baseline in Average Pain Intensity Numeric Rating Scale (API-NRS) Score for GOA1 Subset

    Time frame: Baseline, Week 80

  43. Change from Baseline in Worst Pain Intensity Numeric Rating Scale (WPI-NRS) Score for GOA1 Subset

    Time frame: Baseline, Week 80

  44. Percentage of Participants with an Improved Categorical Shift in Patient Global Impression of Severity (PGIS) - Target Knee Function for GOA1 Subset

    Time frame: Baseline through Week 80

  45. Percentage of Participants with an Improved Categorical Shift in PGIS - Target Knee Pain for GOA1 Subset

    Time frame: Baseline through Week 80

  46. Change from Baseline in EQ-5D-5L for GOA1 Subset

    Time frame: Baseline, Week 80

  47. Percentage of Participants with a Change in Use of Allowed Concomitant Pain Medication for GOA1 Subset

    Time frame: Baseline through Week 80

  48. Change from Baseline in Joint Space Width for GOA1 Subset

    Time frame: Baseline, Week 80

  49. Pharmacokinetics (PK): Steady State Area Under the Concentration Time Curve (AUC)

    AUC is presented as a single average measure of AUC across the study duration.

    Time frame: Baseline through Week 80

07

Study locations

134 sites
  • Central Phoenix Medical Clinic
    Phoenix, Arizona 85020, United States
  • Arizona Research Center
    Phoenix, Arizona 85053, United States
  • Medical Investigations
    Little Rock, Arkansas 72211, United States
  • Neuro-Pain Medical Center
    Fresno, California 93710, United States
  • Valley Research
    Fresno, California 93720, United States
  • Artemis Institute for Clinical Research
    San Diego, California 92103, United States
  • University of Colorado Anschutz Medical Campus
    Aurora, Colorado 80045, United States
  • Yale University School of Medicine
    New Haven, Connecticut 06519, United States
  • Chase Medical Research, LLC
    Waterbury, Connecticut 06708, United States
  • Teradan Clinical Trials, LLC
    Brandon, Florida 33511, United States
  • Suncoast Research Group
    Miami, Florida 33135, United States
  • New Horizon Research Center
    Miami, Florida 33165, United States
  • Clinical Neuroscience Solutions
    Orlando, Florida 32801, United States
  • Progressive Medical Research
    Port Orange, Florida 32127, United States
  • NeuroTrials Research Inc
    Atlanta, Georgia 30328, United States
  • North Georgia Clinical Research
    Woodstock, Georgia 30189, United States
  • East-West Medical Research Institute
    Honolulu, Hawaii 96814, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Central Illinois Diabetes and Clinical Research a Division of Prairie Education and Research Cooperative
    Springfield, Illinois 62711, United States
  • Brengle Family Medicine
    Indianapolis, Indiana 46260, United States
  • Cotton O'Neil Diabetes & Endocrinology
    Topeka, Kansas 66606, United States
  • MedVadis Research Corporation
    Waltham, Massachusetts 02451, United States
  • Great Lakes Research Group, Inc.
    Bay City, Michigan 48706, United States
  • StudyMetrix Research
    City of Saint Peters, Missouri 63303, United States
  • Clinvest Research LLC
    Springfield, Missouri 65807, United States
  • Palm Research Center Tenaya
    Las Vegas, Nevada 89128, United States
  • Rochester Clinical Research, LLC
    Rochester, New York 14609, United States
  • Carteret Medical Group
    Morehead City, North Carolina 28557, United States
  • Trial Management Associates - Wilmington - Floral Parkway
    Wilmington, North Carolina 28403, United States
  • Lillestol Research
    Fargo, North Dakota 58104, United States
  • Altoona Center For Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Tribe Clinical Research, LLC
    Greenville, South Carolina 29607, United States
  • Tribe Clinical Research - Spartanburg
    Spartanburg, South Carolina 29301, United States
  • Vanderbilt Health One Hundred Oaks
    Nashville, Tennessee 37204, United States
  • FutureSearch Trials of Neurology
    Austin, Texas 78731, United States
  • Juno Research
    Houston, Texas 77040, United States
  • Advanced Research Institute
    Ogden, Utah 84405, United States
  • Northwest Clinical Research Center
    Bellevue, Washington 98007, United States
  • Rainier Clinical Research Center
    Renton, Washington 98057, United States
  • Emeritus Research
    Botany, New South Wales 2019, Australia
  • The AIM Centre / Hunter Diabetes Centre
    Merewether, New South Wales 2291, Australia
  • Logan Hospital
    Meadowbrook, Queensland 4131, Australia
  • Fusion Clinical Research
    Adelaide, South Australia 5000, Australia
  • Nightingale Research
    Adelaide, South Aust 5000, Australia
  • Emeritus Research
    Camberwell, Victoria 3124, Australia
  • Barwon Health
    Geelong, Victoria 3220, Australia
  • One Clinical Research
    Nedlands, Western Australia 6009, Australia
  • CPQuali Pesquisa Clínica
    São Paulo, São Paulo 01228-000, Brazil
  • CPCLIN
    São Paulo, São Paulo 01228-200, Brazil
  • CEPIC - Centro Paulista de Investigação Clínica
    São Paulo, São Paulo 04266-010, Brazil
  • Aggarwal and Associates Limited
    Brampton, Ontario L6T 0G1, Canada
  • Dr. Steven V. Zizzo Medicine Professional Corporation
    Hamilton, Ontario L8J 0B6, Canada
  • Wharton Medical Clinic
    Hamilton, Ontario L8L 5G8, Canada
  • Your Research Network
    Niagara Falls, Ontario L2H 1H5, Canada
  • Bluewater Clinical Research Group Inc.
    Sarnia, Ontario N7T 4X3, Canada
  • Canadian Phase Onward
    Toronto, Ontario M3J 0K2, Canada
  • Centre de Recherche Clinique de Laval
    Laval, Quebec H7T 2P5, Canada
  • Clinique de médecine Urbaine du Quartier Latin
    Montreal, Quebec H2L 4E9, Canada
  • C.I.C. Mauricie inc.
    Trois-Rivières, Quebec G8T 7A1, Canada
  • Óbudai Egészségügyi Centrum
    Budapest, Budapest 1036, Hungary
  • ClinDiab Kft.
    Budapest, Budapest 1089, Hungary
  • Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ
    Szeged, Csongrád megye 6725, Hungary
  • Debreceni Egyetem Klinikai Központ
    Debrecen, Debrecen 4031, Hungary
  • Debreceni Egyetem Klinikai Kozpont
    Debrecen, Debrecen 4032, Hungary
  • Regia Med Kft
    Székesfehérvár, Fejér 8000, Hungary
  • Medifarma 98 Kft
    Nyíregyháza, Nyíregyháza 4400, Hungary
  • DRC Gyógyszervizsgáló Központ
    Balatonfüred, Veszprém megye 8230, Hungary
  • Endolife Speciality Hospitals
    Guntur, Andhra Pradesh 522001, India
  • Avron Hospitals
    Ahmedabad, Gujarat 380013, India
  • Surat Institute of Digestive Sciences Hospitals
    Surat, Gujarat 395002, India
  • Karnataka Institute of Medical Sciences
    Hubli, Karnataka 580021, India
  • Indian Institute of Diabetes
    Thiruvananthapuram, Kerala 695031, India
  • Jothydev's Diabetes and Research Center
    Trivandrum, Kerala 695032, India
  • Wockhardt Hospital - Mumbai Central
    Mumbai, Maharashtra 400011, India
  • Deenanath Mangeshkar Hospital & Research Centre
    Pune, Maharashtra 411004, India
  • Chellaram Diabetes Institute
    Pune, Maharashtra 411021, India
  • Lifepoint Multispeciality Hospital
    Pune, Maharashtra 411057, India
  • All India Institute of Medical Sciences
    Bhubaneswar, Odisha 751019, India
  • Eternal Heart Care Center and Research Institute
    Jaipur, Rajasthan 302020, India
  • Christian Medical College Vellore
    Vellore, Tamil Nadu 632004, India
  • ILS Hospitals
    Kolkata, West Benga 700064, India
  • Centro de Atención e Investigación Clínica
    Aguascalientes, Aguascalientes 20119, Mexico
  • Investigacion En Salud Y Metabolismo S.C / Nutricion Clinica / Unidad de Base de Datos
    Chihuahua City, Chihuahua 31110, Mexico
  • Centro de Investigacion en Artritis y Osteoporosis SC
    Mexicali, Estado de Baja California 21200, Mexico
  • Diseno y Planeacion en Investigacion Medica
    Guadalajara, Jalisco 44130, Mexico
  • Clinica de Investigacion en Reumatologia y Obesidad S. C.
    Guadalajara, Jalisco 44650, Mexico
  • Private Practice - Dr. Arechavaleta Granell Maria del Rosario
    Guadalajara, Jalisco 44670, Mexico
  • Unidad de Investigación Clínica y Atención Médica HEPA
    Guadalajara, Jalisco 44670, Mexico
  • RM Pharma Specialists
    Mexico City, Mexico City 03100, Mexico
  • Clinica Omega
    Mexico City, Mexico City 06700, Mexico
  • Instituto de Diabetes, Obesidad y Nutricion
    Cuernavaca, Morelos 62250, Mexico
  • Unidad biomedica avanzada monterrey
    Monterrey, Nuevo León 64460, Mexico
  • Hospital Universitario Dr. Jose Eleuterio Gonzalez
    Monterrey, Nuevo León 66460, Mexico
  • Arké SMO S.A de C.V
    Veracruz, Veracruz 91910, Mexico
  • EME RED Hospitalaria
    Mérida, Yucatán 97000, Mexico
  • Kohler and Milstein Research S.A. de C.V.
    Mérida, Yucatán 97070, Mexico
  • Centrum Zdrowia Metabolicznego Pawel Bogdanski
    Poznan, Greater Poland Voivodeship 60-589, Poland
  • INTERCOR
    Bydgoszcz, Kuyavian-Pomeranian Voivodeship 85-605, Poland
  • Private Practice - Dr. Robert Witek
    Tarnów, Lesser Poland Voivodeship 33-100, Poland
  • CenterMed Lublin NZOZ
    Lublin, Lublin Voivodeship 20-044, Poland

Showing the first 100 of 134 sites across 12 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication or approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2023 to primary completion in Apr 2026, 32 months.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 32 months is above that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2023
First posted
Jul 3, 2023
StartActual
Jul 10, 2023
Primary completionActual
Apr 6, 2026
CompletionActual
Apr 30, 2026
Last update
Aug 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05929066
Responsible party
Sponsor
First posted
Jul 3, 2023
Start date
Jul 10, 2023
Primary completion
Apr 6, 2026
Completion
Apr 30, 2026
Last update
Aug 21, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern Time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Retatrutide

Start the discussion